Full Text:


Ǵм Vol.24_No.2 Suppl. P.S221-233, Dec. 2007


ȯ ֽ

Clinical Update: Inflammatory Bowel Disease

б ǰ б
åڣ庴, 뱸 317, б ǰ б
Tel: (053) 620-3831, Fax: (053) 654-8386
E-mail: jbi@med.yu.ac.kr

December 30, 2007


Inflammatory bowel disease(IBD) which is well known as Crohns disease and ulcerative colitis is a chronic disorder that repeats improvement and exacerbation. The possible causes of the disease are environmental factors, genetic factors and immune deficiency resulted from bacterial infection. Recently, IL-23 is proved to be a main cytokine which has a central role in Crohns disease. The diagnosis of IBD is made by clinical manifestation, serologic test, endoscopic finding and histologic finding. The mainstay of remission and maintenance therapy of ulcerative colitis is 5-aminosalicylate(5-ASA). Steroid can be used in severe or refractory case and nowadays, budesonide shows a good effect with minimal side effects. In cases of steroid dependent, we can use the immunomodulators such as azathioprine, cyclosporin and 6-thioguanine. The cytokine associated with inflammation of IBD has been emphasized and the treatment which targets the cytokine such as tumor necrosis factor is tried. Infliximab and adalimumab block tumor necrosis factors-a and they are proved the efficacy by many clinical trial. Leukocytapheresis(LCAP) is tried in ulcerative colitis since 1980 in Japan. When we treat IBD patients, we need to consider all the things such as safety, side effects and economy of the patients. We expect that the development of new biologic agent which is more cost effective and more effect with more convinience.

Key Words: Inflammatory bowel disease, Pathogenesis, Treatment


1. Probert CS, Jayanthi V, Hughes AO, Thompson JR, Wicks AC, Mayberry JF. Prevalence and family risk of ulcerative colitis and Crohns disease: an epidemiological study among Europeans and South Asians in Leicestershire. Gut 1993 Nov;34(11):1547-51.

2. Lewis CM, Whitwell SC, Forbes A, Sanderson J, Mathew CG, Marteau TM. Estimating risks of common complex diseases across genetic and environmental factors: the example of Crohn disease. J Med Genet 2007 Nov;44(11): 689-94.

3. Koloski NA, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: A critical review of the literature. World J Gastroenterol 2008 Jun; 14(2): 165-73.
4. Elliott DE, Urban JF, Argo CK, Weinstock JV. Does the failure to acquire helminthic parasites predispose to Crohns disease. FASEB J 2000 Sep;14(12):1848-55.

5. Maizels RM, Yazdanbakhsh M. Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat Rev Immunol 2003 Sep;3(9):733-44.
6. Weinstock JV, Summers R, Elliott DE. Helminths and harmony: mounting evidence suggests that helminths help regulate mucosal inflam- mation. Gut 2004 Jan;53(1):7-9.

7. Hunter MM, McKay DM. Review article: helminths as therapeutic agents for inflammatory bowel disease. Aliment Pharmacol Ther 2004 Jan 15;19(2):167-77.
8. Fox JG, Beck P, Dangler CA, Whary MT, Wang TC, Shi HN, et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy. Nat Med 2000 May;6(6):536-42.

9. Khan WI, Blennerhasset PA, Varghese AK, Chowdhury SK, Omsted P, Deng Y, et al. Intestinal nematode infection ameliorates experimental colitis in mice. Infect Immun 2002 Nov;7(10):5931-7.
10. Elliott DE, Setiawan T, Metwali A, Blum A, Urban JF, Weinstock JV. Heligomonsomoides polygyrus inhibits established colitis in IL-10- deficient mice. Eur J Immunol 2004 Oct;34 (10):2690-8.

11. Moreels TG, Nieuwendijk RJ, De Man JG, De Winter BY, Herman AG, Van Marck EA, et al. Concurrent infection with Schistosoma mansoni attenuates inflammation-induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats. Gut 2004 Jan;53(1):99-107.

12. Feller M, Huwiler K, Stephan R, Altpeter E, Shang A, Furrer H, et al. Mycobacterium avium subspecies paratuberculosis and Crohns disease: a systematic review and meta-analysis. Lancet Infect Dis 2007 Sep;7(9):607-13.

13. Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: Good, bad or ugly? World J Gastroenterol 2007 Dec 14;13 (46):6134-9.
14. Seidelin JB, Nielsen OH. Transdermal nicotine treatment of ulcerative colitis: a survey of a Cochrane review. Ugeskr Laeger 2006 Feb 13;168(7):674-7.

15. Ingram JR, Rhodes J, Evans BK, Newcombe RG, Thomas GA. Comparative study of enema retention and preference in ulcerative colitis. Postgrad Med J 2005 Sep;81(959):594-8.

16. de Saussure P, Clerson P, Prost PL, Truong Tan TN, Bouhnik Y, Gil-Rch. Appendectomy, smoking habits and the risk of developing ulcerative colitis: a case control study in private practice setting. Gastroenterol Clin Biol 2007 May;31(5):493-7.

17. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos, et al. Aframe shift in NOD2 associated with susceptibility to Crohns disease. Nature 2001 May 31;411(6837):603-6.
18. Duerr RH, Taylor KD,Brant SR, Rioux JP, Silverberg MS, Daly MJ, et al. A genome- wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006 Dec 1;314(5804):1461-3.

19. Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med 2007 Jan;13(1):26-8.
20. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflam- matory bowel disease. Aliment Pharmacol Ther 2007 Feb 1;25(3):247-55.

21. Sipponen T, Savilahti E, Kolho KL, Nuttinen H, Turunen H, Farkkila M. Crohns disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohns disease activity index and endoscopic findings. Inflamm Bowel Dis 2008 Jan;14(1):40-6.

22. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005 Aug;11(8):707-12.

23. Reese GE, Constantinides VA, Simillis C, Darz AW, Orchard TR, Fazio VW, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006 Oct;101(10): 2410-22.

24. Joossens S, Vermeire S, Van Steen K, Godefridis G, Claessens G, Pierik M, et al. Pancreatic autoantibodies in inflammatory bowel disease. Inflamm Bowel Dis 2004 Nov;10(6):771-7.
25. Castro-Santos P, Mozo L, Gutierrez C, Saurez A. TNFalpha genotype influences development of IgA-ASCA antibodies in Crohns disease patients with CARD15 wild type. Clin Immunol 2006 Dec;121(3):305-13.

26. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004 Nov;99(11):2235-41.

27. Ando T, Takashi H, Watanabe O, Maeda O, Ishiguro K, Ishiguro K, et al. Magnifying chromoscopy, a novel and useful technique for colonoscopy in ulcerative colitis. World J Gastroenterol 2007 May 14;13(18):2523-8.

28. Hurlstone DP, Sanders DS, Lobo AJ, McAlindon ME, Cross SS. Indigo carmine-assisted high- magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy 2005 Dec;37 (12):1186-92.
29. Ochsenkuhn T, Tillack C, Stepp H, Diebold J, Ott SJ, Baumgartner R, et al. Low frequency of colorectal dysplasia in patients with long- standing inflammatory bowel disease colitis: detection by fluorescence endoscopy. Endoscopy 2006 May;38(5):477-82.

30. Triester SL, Leighton JA, Leontiadis GI, Gurudu SR, Fleischer DE, Hara AK, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease. Am J Gastroenterol 2006 May;101(5):954-64.

31. Hanauer SB. Review article: high-dose amino- salicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther 2006 Oct;24 Suppl 3:37-40.

32. Rubin DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol 2005 Jun;100(6):1354-6.
33. Gionchetti P, Rizzello F, Habal G, Morselli C, Amandini C, Romaganoli R, et al. Standard treatment of ulcerative colitis. Dig Dis 2003; 21(2):157-67.

34. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohns disease. Aliment Pharmacol Ther 2002 Aug;16(8):1509-17.

35. Chopra A, Pardi DS, Loftus EV Jr, Tremaine WJ, Faubion WA, Hanson KA, et al. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bowel Dis 2006 Jan;12(1):29-32.

36. Ginsburg PM, Dassopoulous T. Steroid dependent ulcerative colitis: azathioprine use is finally evidence-based. Inflamm Bowel Dis 2006 Sep;12(9):921-2.

37. Minami M, Ohta M, Ohkura T, Ando T, Ohmiya N, Niwa Y, et al. Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. World J Gastroenterol 2007 Feb 7;13(5):754-60.

38. Swaminth A, Lichtiger S. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohns colitis. Inflamm Bowel Dis 2008 Feb;14(2):213-6.

39. Richter JA, Bickston SJ. Infliximab use in luminal Crohns disease. Gastroenterol Clin North Am 2006 Dec;35(4):775-93.
40. Bressler B, Sands BE. Review article: Medical therapy for fistulizing Crohns disease. Aliment Pharmacol Ther 2006 Nov 1;24(9):1283-93.

41. Sands BE, Blank MA, Diamond RH, Barret JP, Van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohns disease: results from the ACCENT II study. Aliment Pharmacol Ther 2006 Apr 15;23(8):1127-36.

42. Hanauer S, Feagan B. Maintenance infliximab for Crohns disease; the ACCENT I randomized trial. Lancet 2002 May 4;359(9317):1541-9.
43. Ainsworth MA, Bendtzen K, Brynskov J. Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohns Disease. Am J Gastroenterol 2007 Nov;102:1-5.

44. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohns disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004 Jan;126 (1):19-31.

45. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor- alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008 Jan 1;27(1):19-30.

46. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, Macintish D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohns disease: the CLASSIC-I trial. Gastroenterology 2006 Feb; 130(2):323-3.

47. Sandborn WJ, Hanauer SB, Rutgeerts PJ, Fedorak RN, Lukas M, Macintosh D, et al. Adalimumab for maintenance treatment of Crohns disease: results of the CLASSIC II trial. Gut 2007 Sep;56(9):1232-9.

48. Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, et al. Pilot feasibility studies of leukacytopheresis with the Adacolumn Apheresis system in patients with active ulcerative colitis or Crohns disease. J Clin Gastroenterol 2006 Jul;40(6):482-9

49. Pineda AA. Developments in the apheresis procedure for the treatment of inflammatory bowel disease. Inflam Bowel Dis 2006 Jan;12 (Suppl 1):S10-4.
50. Kanke K, Nakano M, Hirashi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy fro active ulcerative colitis. Dig Liver Dis 2004 Dec;36(12):811-7.

51. Summers RW, Elliott DE, Qadir JF, Urban JF Jr, Thompson R, Weinstock JV. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 2003 Sep;98(9):2034-41.

52. Summers RW, Elliott DE, Urban JF, Thompson R. Weinstock JV. Trichuris suis therapy in Crohns disease. Gut 2005 Jan;54(1):87-90.
53. Summers RW, Elliott DE, Urban JF, Thompson RA. Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005 Apr;128(4):825-32.